CF PharmTech Closes US$ 90 Million Financing Round to Accelerate Global Development of Respiratory Drugs

พฤหัสบดี 2 มกราคม 2563 เวลา 08:55 น.

CF PharmTech, Inc., a pharmaceutical company with a vision to provide quality and affordable respiratory drug products globally, announced it has raised a $9CF PharmTech million Series E investment led by New Alliance Capital. The investment included participation from new investors CR-CP Life Science Fund, Finnova Capital, GT Capital, Co-stone Asset Management, Xiangcheng Financial Holdings, Everest Venture Capital, and existing investors, such as Oriza Holdings, Longmen Venture Capital, GTJA Investment and CMB International.

The completion of this round of funding reflects the strong support from China's investors to fuel high-caliber pharmaceutical companies that have a strong global competitive edge, and will allow CF PharmTech to bring products in its pipeline to market.

With respect to this round of financing, New Alliance Capital Executive Director Lei Cai explained: "New Alliance Capital prioritizes investment opportunities in the healthcare industries. Respiratory treatments and inhaled medications, in particular, are promising because of the high technological barriers to entry and immense potential for growth. CF PharmTech has worked meticulously to build strong technological platforms that support the development of a comprehensive range of products. The integrity and professionalism of the core team at CF PharmTech impressed us deeply."

CR-CP Life Science Fund Managing Director Da Liu explained: "CF PharmTech is one of China's most innovative and pioneering pharmaceutical companies to focus on respiratory disease treatments. As a pharma company, CF PharmTech fully embodies a commitment to quality and global standards. As one of the few leading private pharmaceutical companies of respiratory drug delivery, CF PharmTech has immense potential for growth."

CEC Capital served as the exclusive financial adviser to CF PharmTech during this Series E round of financing. CEC Capital Partner Irene Hong had this to say: "The close of this financing round will mark a new stage in the product development at CF PharmTech. We greatly admire the persevering spirit of the CF PharmTech team."

About CF PharmTech:

CF PharmTech is a pharmaceutical company dedicated to respiratory health. Since its inception, the company has already established state of the art R&D and manufacturing facilities for inhalation products. Currently, CF PharmTech has a growing pipeline of over 2CF PharmTech products that are headed to China and global markets. Learn more about CF PharmTech, visit www.cfpharmtech.com.

Photo - https://photos.prnasia.com/prnh/2CF PharmTech191227/2679726-1

Caption: CF PharmTech's manufacturing facility

CF PharmTech Closes US$ 90 Million Financing Round to Accelerate Global Development of Respiratory Drugs

ข่าวCF PharmTech+o:prncnวันนี้

ChuanQi IP, "MIR2M: The Grandmaster" Release Airdrop Event in Progress

3rd Mobile Title Based on "The Legend of Mir 2" Universe Features Various Contents such as PvP Battles, Boss Dungeons, Guild System Commemorative Events Include Mission Completion, Gameplay Review Video Production ChuanQi IP, a subsidiary of WEMADE (CEO: Henry Chang), has officially released the blockchain-based idle martial arts RPG, "MIR2M: The Grandmaster," today (2nd). "MIR2M: The Grandmaster" is the third title in the MIR2M series. Based on "The Legend of Mir 2" universe, it tells the story

02 กุมภาพันธ์ 2567 09:00 น.

ฉวนฉี ไอพี จัดกิจกรรมแอร์ดรอปฉลองการเปิดตัวเกม "MIR2M: The Grandmaster" — เกมมือถือเกมที่ 3 ในจักรวาล "The Legend of Mir 2" อัดแน่นด้วยคอนเทนต์หลากหลาย ทั... ก.พ. 67

CF PharmTech จับมือ Chengdu Shangyi เปิดตัว "โปรแกรมฟื้นฟูสุขภาพที่บ้านสำหรับผู้ป่วยโควิด-19 ที่รักษาหายแล้ว" พร้อมปล่อยแอป "R Plus Health" ให้ใช้ฟรีทั่วโลก — CF PharmTec... ก.พ. 64

CF PharmTech and Chengdu Shangyi Launch the "Home-Based Recovery Program for Discharged Covid-19 Patients" and Announce Today's Global Release of the "R Plus Health" Free App — CF PharmTec... ก.พ. 64

CF PharmTech ปิดระดมทุน Series F วงเงิน 50 ล้านดอลลาร์ เร่งผลิตยาสูดพ่นออกสู่ตลาด — CF PharmTech, Inc. ประกาศว่า บริษัทได้รับเงินลงทุน 50 ล้านดอลลาร์สหรัฐ... ก.ค. 63

CF PharmTech, Inc. Closes a US $50M Series F Financing to Accelerate the Commercialization of its Inhalation Products. — CF PharmTech, Inc. ("CF PharmTech... ก.ค. 63

CF PharmTech ปิดระดมทุนวงเงิน 90 ล้านดอลลาร์สหรัฐ มุ่งพัฒนายารักษาโรคระบบทางเดินหายใจ — CF PharmTech, Inc. บริษัทเภสัชกรรมที่มีวิสัยทัศน์เพื่อพัฒนาและผลิต... ม.ค. 63

CF PharmTech Closes US$ 90 Million Financing Round to Accelerate Global Development of Respiratory Drugs — CF PharmTech, Inc., a pharmaceutical company wi... ม.ค. 63

CF PharmTech ระดมทุน 65 ล้านดอลลาร์ เพื่อเร่งพัฒนาผลิตภัณฑ์ยาสูดพ่นและขยายกำลังผลิตสู่ตลาดโลก

CF PharmTech, Inc. ("CF PharmTech") บริษัทเวชภัณฑ์เฉพาะทางชั้นนำผู้พัฒนาและผลิตผลิตภัณฑ์ยาสูดพ่น ประกาศว่า บริษัทระดมทุนได้ 65 ล้านดอลลาร์สหรัฐในการระดมทุนรอบ Series D โดยมี Future Industry Investment Fund... ส.ค. 60

CF PharmTech, Inc. Raises USD $65 Million to Accelerate the Development of Company's Inhalation Products and Manufacturing Capacity to Global Market

CF PharmTech, Inc. ("CF PharmTech"), a leading specialty pharmaceutical company that develops and manufactures inhalation products, announced today that... ส.ค. 60